GlassScriptPhysician profile
Tabitha M Horn
NPI 1275122897
$4,185.63
in general payments reported to CMS, 2019-2025
26 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $118 · 2023: $679 · 2024: $1,405 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.10 |
| Education | $198.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $961.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $718.08 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $524.36 | 2024-2025 | Cuvitru, Hyqvia, Eohilia |
| Glaxosmithkline, LLC. | $440.76 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Csl Behring | $413.70 | 2021-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $175.52 | 2025 | |
| Blueprint Medicines Corporation | $119.16 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $114.56 | 2024-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Octapharma USA, INC. | $89.10 | 2021-2025 | Cutaquig, Panzyga |
| Astrazeneca Pharmaceuticals LP | $74.70 | 2021-2025 | Fasenra, Breztri |
| Kaleo, INC. | $61.18 | 2023 | Auvi-Q |
| Lilly USA, LLC | $54.94 | 2024-2025 | Ebglyss |
| Galderma Laboratories, L.P. | $52.47 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $50.07 | 2023-2024 | Ruconest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $46.61 | 2023-2025 | Adbry |
| Amgen INC. | $27.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.29 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.10 | 2025 | Xhance, Nuzyra |
| Optinose US, INC. | $18.38 | 2025 | |
| Verona Pharma, INC. | $18.01 | 2025 | Ohtuvayre |
| Abbvie INC. | $17.93 | 2023 | |
| Hikma Pharmaceuticals USA | $16.95 | 2025 | Ryaltris |
| Adma Biomanufacturing LLC | $15.61 | 2021 | |
| Grifols USA, LLC | $15.34 | 2023 | Xembify |
| Biohaven Pharmaceutical Holding Company LTD. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.